Trial Profile
A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients With Non-muscle Invasive Bladder Cancer at High Risk of Progression Who Are Refractory to Bacillus Calmette-Guerin Therapy and Who Are Medically Unfit for/Refuse Cystectomy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs TLD 1433 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; First in man
- Acronyms Study I
- Sponsors Theralase Technologies
- 01 Jul 2022 Results assessing safety and tolerability of PDT, with secondary objectives of (1) pharmacokinetic (PK) properties of TLD-1433 and (2) efficacy, as evaluated by recurrence-free survival and complete response (CR) published in the European Urology Open Science
- 21 Jun 2022 According to a Theralase Technologies media release, data published in the European Urology Open Science (EUOS) Journal.
- 17 Aug 2018 Status changed from recruiting to completed.